NasdaqCM - Delayed Quote USD

Novo Integrated Sciences, Inc. (NVOS)

0.5190 -0.0066 (-1.26%)
At close: April 26 at 4:00 PM EDT
0.5290 +0.01 (+1.93%)
After hours: April 26 at 7:59 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
8/31/2023
8/31/2022
8/31/2021
8/31/2020
Total Revenue
13,658.0400
12,572.0190
11,737.9370
9,305.2550
7,860.5670
Cost of Revenue
8,147.6570
7,619.3040
6,938.6990
5,482.2570
4,802.1950
Gross Profit
5,510.3830
4,952.7150
4,799.2380
3,822.9980
3,058.3720
Operating Expense
14,892.1800
13,505.8770
14,385.3410
8,097.1660
7,291.2260
Operating Income
-9,381.7970
-8,553.1620
-9,586.1030
-4,274.1680
-4,232.8540
Net Non Operating Interest Income Expense
-3,059.0810
-5,108.6650
-7,399.1600
-119.3160
-123.0350
Other Income Expense
347.0490
392.3830
-16,082.2170
-77.4510
-568.3200
Pretax Income
-12,093.8290
-13,269.4440
-33,067.4800
-4,470.9350
-4,924.2090
Tax Provision
--
--
-22.3020
--
--
Net Income Common Stockholders
-12,084.2550
-13,214.5520
-32,849.2150
-4,462.1470
-4,915.1540
Diluted NI Available to Com Stockholders
-12,084.2550
-13,214.5520
-32,849.2150
-4,462.1470
-4,915.1540
Basic EPS
-0.21
-1.30
-11.28
-1.80
-2.10
Diluted EPS
-0.21
-1.30
-11.28
-1.80
-2.10
Basic Average Shares
15,934.3640
10,165.5480
2,913.2630
2,477.4450
2,303.4080
Diluted Average Shares
15,934.3640
10,165.5480
2,913.2630
2,477.4450
2,303.4080
Total Operating Income as Reported
-9,381.7970
-8,553.1620
-25,026.6770
-4,373.5190
-4,262.5980
Total Expenses
23,039.8370
21,125.1810
21,324.0400
13,579.4230
12,093.4210
Net Income from Continuing & Discontinued Operation
-12,084.2550
-13,214.5520
-32,849.2150
-4,462.1470
-4,915.1540
Normalized Income
-12,784.6520
-12,999.3460
-16,766.9980
-4,362.7960
-4,540.8890
Interest Income
9.1990
9.0270
169.0880
45.6870
33.6270
Interest Expense
3,068.2800
5,117.6920
7,568.2480
165.0030
156.6620
Net Interest Income
-3,059.0810
-5,108.6650
-7,399.1600
-119.3160
-123.0350
EBIT
-9,025.5490
-8,151.7520
-25,499.2320
-4,305.9320
-4,767.5470
EBITDA
-6,720.9790
-5,848.9980
-22,479.9790
-2,581.8100
-3,322.4710
Reconciled Cost of Revenue
8,147.6570
7,619.3040
6,938.6990
5,482.2570
4,802.1950
Reconciled Depreciation
2,304.5700
2,302.7540
3,019.2530
1,724.1220
1,445.0760
Net Income from Continuing Operation Net Minority Interest
-12,084.2550
-13,214.5520
-32,849.2150
-4,462.1470
-4,915.1540
Total Unusual Items Excluding Goodwill
700.3970
-215.2060
-16,082.2170
-99.3510
-374.2650
Total Unusual Items
700.3970
-215.2060
-16,082.2170
-99.3510
-374.2650
Normalized EBITDA
-7,421.3760
-5,633.7920
-6,397.7620
-2,482.4590
-2,948.2060
8/31/2020 - 2/23/2021

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

NIVF NewGenIvf Group Limited
1.7800
+36.92%
 
BACK IMAC Holdings, Inc.
3.9200
-23.14%
 
IONM Assure Holdings Corp.
0.6960
-21.71%
 
AMS American Shared Hospital Services
3.1700
+1.60%
 
SYRA Syra Health Corp.
1.0700
+4.90%
 
NIVFW NewGenIvf Group Limited
0.1000
+45.77%
 
AIH Aesthetic Medical International Holdings Group Limited
0.4301
-8.49%
 
TOI The Oncology Institute, Inc.
1.1500
-2.54%
 
CCEL Cryo-Cell International, Inc.
8.45
+8.33%
 
AGL agilon health, inc.
5.0000
-2.53%